相关临床试验
7
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
1
14.3%
已完成
6
85.7%
暂无批准数据
- Humanetics Corporation's BIO 300 demonstrated statistically significant improvement in pulmonary function (FEV1) at 12 weeks, maintained at 12 months in post-COVID-19 patients. - The Phase 2 trial also showed trends toward improved pulmonary function (DLCO, FVC) and enhanced quality of life in BIO 300-treated participants. - BIO 300 was well-tolerated, with adverse events consistent with the patient population, and no new safety concerns were identified during the trial. - Humanetics is further evaluating BIO 300 for COVID-19 and other conditions involving lung inflammation, as well as medical countermeasure and oncology applications.
- Humanetics Corporation secured an additional $5 million from the Department of Defense to further develop BIO 300, a drug aimed at mitigating harm from acute radiation exposure. - The funding will support manufacturing enhancements for both the drug substance and product of BIO 300, strengthening domestic production capabilities within the United States. - Clinical and nonclinical studies of BIO 300 will also be supported, accelerating its development towards FDA approval and potential emergency use authorization. - BIO 300 is being developed as a medical countermeasure for acute radiation syndrome, addressing a critical need for prophylactic radioprotectants for military, first responders, and civilians.
